# Invea Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/invea-therapeutics

- Industry: Biotechnology
- Headquarters: Guilford, US
- Total disclosed funding: $1.5M
- Latest round: Series A (Apr 7, 2022)
- Investors on record: 1

## About

Based in Connecticut, US, and founded in 2021, Invea Therapeutics, Inc. is a biotechnology company that develops medicines designed for immune-mediated inflammatory disorders (IMIDs). The company was founded by its CEO and president, Krishnan Nandabalan. In April 2022, Invea Therapeutics, Inc. raised USD 1.53 million in venture funding from Connecticut Innovations.

The company develops precision medicines for individuals suffering from gastrointestinal and hepatobiliary disorders. The firm employs AI to decode the intricate relationship known as the gut-brain axis (GBA) that integrates various types of data, encompassing biology, symptomatology, and pharmacology. Invea's focus on innate immunity, inflammasome biology, and neuroinflammation provides a precision medicine approach to address the root causes of disorders affected by the GBA. The company’s pipeline programs include INVA8001, INVA8002, INVA8003, and the discovery pipeline.

The organization intends to go public on the Nasdaq (INAI).

## Funding rounds

- Series A, Apr 7, 2022, $1.5M — Connecticut Innovations

## Investors

- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A